Form 4: TriSalus Life Sciences CFO Acquires Shares
Insider Transaction Filing
TriSalus Life Sciences, Inc. reports a transaction where Chief Financial Officer David Patience acquired shares through a tax withholding arrangement.
Summary
- David Patience, Chief Financial Officer of TriSalus Life Sciences, Inc., acquired 14,650 shares of common stock on July 1, 2026.
- The acquisition was a result of shares being withheld by the Issuer to cover the Reporting Person's tax obligations related to the vesting of previously granted restricted stock units.
- The transaction price was $4.46 per share.
- Following this transaction, David Patience beneficially owns 261,107 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing. The transaction is a routine tax withholding event related to vested stock, rather than a discretionary purchase or sale, thus having minimal direct impact on sentiment.
Positives
- The Chief Financial Officer has acquired additional shares, indicating continued investment and confidence in the company.
- The acquisition was part of a standard tax withholding process for vested restricted stock units, suggesting normal operational activity.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing.
Industry Context
StockSavvy.ai notes that Form 4 filings, like this one from TriSalus Life Sciences, Inc., are standard disclosures for insider transactions. These filings provide transparency into the holdings and activities of company executives and directors, which can be a signal to the market, though the specific nature of this transaction (tax withholding) is routine.
Stakeholder Impact
- Shareholders: The transaction provides transparency into insider holdings but does not represent a new investment decision by management, thus likely having minimal immediate impact on shareholder perception.
Key Dates
| Date | Description |
|---|---|
| 07/01/2026 | Transaction Date for acquisition of common stock. |
| 07/06/2026 | Date of signature for the filing. |
Keywords
TriSalus Life Sciences, TLSI, Form 4, insider transaction, stock acquisition, CFO, restricted stock units, tax withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.